Summary & Overview

Skin Graft Except for Skin Ulcer or Cellulitis with CC: Inpatient Reimbursement Overview

DRG 577 groups inpatient admissions for skin graft procedures excluding skin ulcer or cellulitis when a Complication or Comorbidity is present, covering grafting for trauma, burns, and surgical defects. Understanding this Diagnosis-Related Group is important because the presence of a Complication or Comorbidity influences resource intensity and Medicare inpatient reimbursement under Centers for Medicare & Medicaid Services payment policies.

Skin Graft Except for Skin Ulcer or Cellulitis with CCDRG Skin Graft Except for Skin Ulcer or Cellulitis with CCDRG 577Diagnosis-Related GroupInpatient ReimbursementMedicarePlastic SurgeryBurn CareWound Care

DRG 577 Overview

DRG 577 covers inpatient admissions for skin graft procedures excluding cases primarily for skin ulcer or cellulitis when a Complication or Comorbidity is present. Typical cases include split-thickness or full-thickness grafting for traumatic wounds, burns, or surgical defects where additional clinical complexity influences resource use. This Diagnosis-Related Group matters for Medicare payment because it groups similar clinical services and drives reimbursement based on the presence of Complication or Comorbidity, affecting payment relative to less or more complex graft admissions. Hospitals use this grouping to classify cases for inpatient prospective payment and billing under Centers for Medicare & Medicaid Services rules.

Clinical Trials

Acute perioperative wound-healing intervention trials assessing novel biologic dressings, growth-factor-containing scaffolds, or negative-pressure therapy protocols to improve graft take and reduce early complications. These studies enroll hospitalized adults undergoing split- or full-thickness skin grafting for traumatic wounds, burns, or surgical defects (excluding ulcers/cellulitis) and measure graft survival, reoperation for graft failure, infection rates, and length of stay. Results are directly relevant to surgeons and hospital payers because improved graft take and fewer complications shorten inpatient stays, reduce returns to the OR, and lower short-term resource utilization.
Comparative effectiveness studies of graft donor-site management and anesthesia/analgesia strategies that evaluate outcomes such as pain control, donor-site healing, and functional recovery. These trials commonly randomize patients receiving skin grafts to different donor-site dressings, local/regional block techniques, or opioid-sparing multimodal analgesia regimens, focusing on adult inpatients and early post-discharge recovery. Findings inform care pathways and bundled-payment decisions by identifying approaches that reduce nursing time, readmissions, and post-acute service use while maintaining graft success.
Post-discharge observational cohorts and registry-based outcomes research tracking long-term functional outcomes, scar quality, and healthcare utilization after skin grafting for non-ulcer/non-cellulitis indications. These studies follow patients after hospital discharge to quantify rates of reoperation, outpatient wound care needs, rehabilitation utilization, and patient-reported outcomes across various comorbidity profiles. This evidence helps payers and health systems predict downstream costs, design targeted care transitions, and stratify patients for intensive follow-up to prevent costly complications and readmissions.

Related Codes

572-SKIN-DEBRIDEMENT-WITHOUT-CC-MCC

Skin Debridement without CC/MCC: Inpatient Reimbursement Overview

580-OTHER-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-PROCEDURES-WITH-CC

Other Skin, Subcutaneous Tissue and Breast Procedures with CC: Inpatient Reimbursement Overview

571-SKIN-DEBRIDEMENT-WITH-CC

Skin Debridement with CC: Inpatient Reimbursement Overview

592-SKIN-ULCERS-WITH-MCC

Skin Ulcers with MCC: Inpatient Reimbursement Overview

583-MASTECTOMY-FOR-MALIGNANCY-WITHOUT-CC-MCC

Mastectomy for Malignancy without CC/MCC: Inpatient Reimbursement Overview

596-MAJOR-SKIN-DISORDERS-WITHOUT-MCC

Major Skin Disorders without MCC: Inpatient Reimbursement Overview

593-SKIN-ULCERS-WITH-CC

Skin Ulcers with CC: Inpatient Reimbursement Overview

585-BREAST-BIOPSY-LOCAL-EXCISION-AND-OTHER-BREAST-PROCEDURES-WITHOUT-CC-MCC

Breast Biopsy, Local Excision and Other Breast Procedures without CC/MCC: Inpatient Reimbursement Overview

605-TRAUMA-TO-THE-SKIN-SUBCUTANEOUS-TISSUE-AND-BREAST-WITHOUT-MCC

Trauma to the Skin, Subcutaneous Tissue and Breast without MCC: Inpatient Reimbursement Overview

595-MAJOR-SKIN-DISORDERS-WITH-MCC

Major Skin Disorders with MCC: Inpatient Reimbursement Overview

Showing 1–10 of 31

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.